Cerestat data

Phase II trial results of Cerestat in 46 stroke patients demonstrated that a fixed dose of a 4.5 mg bolus followed by 0.75 mg/hr for 12 hours was safe and well-tolerated, and showed a trend toward greater neurological improvement in those treated than for those on placebo.

Results were presented at the American Heart Association's International Joint Conference on Stroke and Cerebral Circulation in San Antonio. The double-blind, placebo-controlled, multi-center study showed that the fixed dose achieved and maintained a drug plasma level that has been shown to be neuroprotective in animal models. ...